CLEVELAND, Jan. 14, 2026 — GenomOncology has partnered with Oregon Health & Science University’s Knight Diagnostics Lab to enhance clinical trial matching for cancer patients by implementing GO’s Clinical Trials Matching Solution.
The solution will integrate into KDL’s decision support workflow to automatically match patients to open precision oncology trials based on molecular profiles and clinical characteristics. It delivers trial details including phase, title, locations, sponsor information and eligibility criteria, and provides transparent explanations for why specific trials or trial arms match a patient’s clinical status. Pathologists and multidisciplinary teams can validate matches and incorporate them into diagnostic reports.
“Access to clinical trials remains a significant barrier in cancer care, with many patients never learning about trials that could benefit them,” said Garreth Hippe, chief commercial officer of GenomOncology. “By embedding clinical trial matching directly into the diagnostic workflow, we’re ensuring that every patient receives personalized trial options at the moment they matter most.”
The partnership aims to address delays and oversights common in traditional trial matching by automating the process and producing rapid, customized matches. KDL pathologists will access clinical trials information through their existing interface after an integration process that takes weeks, allowing providers to review and select relevant trials for inclusion in reports delivered to treating physicians and patients.
“At the Knight Diagnostics Lab, our mission is to provide clinicians and patients with the most comprehensive, actionable information to guide treatment decisions,” said Dr. Brian Druker, CEO of the OHSU Knight Cancer Institute. “GenomOncology’s Clinical Trials Matching Solution enhances our ability to connect patients with cutting-edge therapeutic options precisely when they need them.”
The implementation at KDL combines molecular diagnostics with intelligent trial matching to support a more patient-centered approach to precision oncology.
About GenomOncology
GenomOncology transforms clinical and molecular data into actionable intelligence for precision cancer care. The company’s AI-enabled reporting solutions provide embedded decision support for NGS analysis and clinical trial optimization that integrate into clinical workflows to support treatment decision-making. Visit www.genomoncology.com.
About OHSU’s Knight Diagnostics Lab
Knight Diagnostics Lab at Oregon Health & Science University offers comprehensive molecular diagnostic services and expert interpretation to guide precision oncology treatment decisions. Visit www.ohsu.edu.
Media contact
GenomOncology
[email protected]
Leave a Reply